Equities

medmix AG

medmix AG

Actions
Health CareMedical Equipment and Services
  • Price (CHF)15.32
  • Today's Change0.18 / 1.19%
  • Shares traded4.84k
  • 1 Year change-26.35%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 10:54 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medmix Systems AG is a Switzerland-based company active in manufacturing of high-precision delivery devices. The Company operates in business areas such as: the dental segment, which provides MIXPAC and transcodent - system solutions that are used to dose, mix and apply various types of dental materials; drug delivery- solutions for the dosage and application of drugs; a surgical segment which provides devices for bone regeneration and tissue healing; an industry segment that specializes in the mixing and dosing of sealants and adhesives through IXPAC , COX and MK; and a beauty segment in which it produces cosmetic applicators through the GEKA brand.

  • Revenue in CHF (TTM)486.60m
  • Net income in CHF300.00k
  • Incorporated2021
  • Employees2.66k
  • Location
    medmix AGNeuhofstrasse 20BAAR 6340SwitzerlandCHE
  • Phone+41 417237300
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
IVF Hartmann Holding AG147.95m15.15m333.60m304.0022.032.2016.142.256.316.3161.6363.070.80153.088.46486,687.508.217.299.998.9053.9053.2910.248.303.89--0.005652.16-1.792.0934.951.49-14.8326.82
Ion Beam Applications SA418.77m-8.90m387.49m1.99k--3.60164.540.9253-0.3139-0.313914.723.640.7022.542.73215,869.60-1.491.55-5.924.3231.3635.23-2.122.380.71031.400.281443.0718.6710.74-250.40---8.06--
Avon Protection PLC222.06m-14.94m414.22m928.00--2.93103.361.87-0.4363-0.38316.494.100.70052.635.48209,652.20-4.71-1.07-5.39-1.2935.2335.51-6.73-1.621.802.920.3822---7.481.85-387.72---1.66-7.86
CellaVision AB59.32m11.83m454.50m223.0038.427.1529.837.665.925.9229.6931.810.7571.688.453,106,469.0015.0915.3017.3418.2467.5269.0319.9419.982.2166.290.0688110.185.9413.1710.128.0030.458.45
Safilo Group SpA1.00bn-24.08m469.64m3.83k--1.2716.500.4692-0.0596-0.05962.480.91651.131.804.91267,693.80-2.87-7.06-4.47-11.3057.1652.70-2.55-6.871.101.940.2848---4.832.39-145.51---15.50--
Advanced Medical Solutions Group plc144.05m18.13m478.76m800.0026.651.7215.723.320.07240.07240.57551.120.44261.755.34--5.576.546.047.0655.5756.7512.5914.824.00--0.036125.831.514.23-22.14-6.7115.6612.32
Stratec SE246.45m11.86m508.88m1.47k42.892.2717.242.060.99910.999120.7518.860.59061.345.11165,771.402.847.073.558.2025.6027.324.819.700.80294.410.382640.81-4.636.88-55.293.30-2.16-7.68
medmix AG486.60m300.00k624.71m2.66k1,510.981.3311.161.280.010.0111.9111.410.46063.656.05183,070.000.06632.060.08462.4932.4136.380.14394.161.232.920.424467.701.991.40-97.41-64.3612.01--
Synsam AB (publ)494.60m26.05m643.27m3.41k24.543.027.281.302.092.0939.6216.960.73562.2213.121,730,149.003.86--5.27--75.50--5.25--0.4922--0.5675--11.90---5.18------
Revenio Group Oyj94.43m18.57m672.40m216.0035.816.8729.997.120.72050.72053.663.760.70695.507.60447,574.1013.9014.3316.7717.9051.0150.7319.6621.131.7928.490.152155.81-0.412525.80-12.1518.7217.676.30
Paul Hartmann AG2.30bn27.76m714.29m10.17k25.620.68475.390.31078.008.00662.57299.401.182.025.72231,438.001.643.872.265.3456.0156.711.392.981.164.870.186542.751.802.12-21.37-18.495.952.71
Draegerwerk AG & Co KGaA3.27bn98.15m852.45m16.48k8.160.57243.470.26075.365.36178.4876.351.112.614.94205,046.003.393.265.034.8743.3244.163.063.051.175.790.166211.3810.785.39271.0533.872.6455.73
El En SpA676.23m47.12m915.79m2.08k19.392.7015.151.350.60380.60388.674.330.95152.044.05332,511.906.887.4312.8313.5239.1438.837.237.631.20232.140.164--2.7814.88-12.4723.49-13.40--
Data as of May 03 2024. Currency figures normalised to medmix AG's reporting currency: Swiss Franc CHF

Institutional shareholders

20.18%Per cent of shares held by top holders
HolderShares% Held
Fidelity Investments Canada ULCas of 29 Feb 20241.33m3.23%
Capital Research & Management Co. (World Investors)as of 18 Aug 20231.25m3.03%
Credit Suisse Asset Management (Schweiz) AGas of 09 Mar 20231.23m2.99%
UBS Asset Management Switzerland AGas of 26 Jan 20241.23m2.99%
The Vanguard Group, Inc.as of 05 Apr 2024888.38k2.15%
Harris Associates LPas of 31 Mar 2024623.48k1.51%
Oddo BHF Asset Management SASas of 28 Mar 2024594.88k1.44%
Dimensional Fund Advisors LPas of 04 Apr 2024408.76k0.99%
Norges Bank Investment Managementas of 31 Dec 2023386.21k0.94%
Z�rcher Kantonalbank (Investment Management)as of 29 Feb 2024375.82k0.91%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.